| Parameter . | Placebo, n = 48 . | Fulacimstat, n = 99 . | Total, n = 147 . |
|---|---|---|---|
| Male sex, % | 40 (83.3) | 84 (84.8) | 124 (84.4) |
| Age, years | 66.5 ± 7.8 | 69.1 ± 6.3 | 68.2 ± 6.9 |
| BMI, kg/m2 | 31.2 ± 4.7 | 31.4 ± 4.9 | 31.3 ± 4.8 |
| Systolic blood pressure, mmHg | 139 ± 16 | 135 ± 13 | 136 ± 14 |
| Diastolic blood pressure, mmHg | 77 ± 9 | 74 ± 10 | 75 ± 10 |
| High albuminuria, % | 32 (66.7) | 78 (78.8) | 110 (74.8) |
| UACR at Visit 1, mg/g | 140 (31–2429) | 129 (29–2165) | 131 (29–2429) |
| eGFR ≤60 mL/min/1.73 m2, % | 22 (45.8) | 49 (49.5) | 71 (48.3) |
| eGFR at Visit 1, mL/min/1.73 m2 | 61.2 ± 16.5 | 60.5 ± 17.2 | 60.8 ± 16.9 |
| Medical history,a % | |||
| Arterial hypertension | 47 (97.9) | 98 (99.0) | 145 (98.6) |
| Cardiovascular comorbidities | 33 (68.7) | 62 (62.6) | 95 (64.6) |
| Hyperlipidaemia/dyslipidaemia | 25 (52.1) | 51 (51.5) | 76 (51.7) |
| Obesity | 19 (39.6) | 41 (41.4) | 60 (40.8) |
| Diabetic neuropathy | 16 (33.3) | 23 (23.2) | 39 (26.5) |
| Diabetic retinopathy | 10 (20.8) | 25 (25.3) | 35 (23.8) |
| Hypercholesterinaemia | 8 (16.7) | 25 (25.3) | 33 (22.4) |
| Comedication,a % | |||
| ACEis | 15 (31.3) | 24 (24.2) | 39 (26.5)b |
| Ang II receptor blockers (%) | 33 (68.7) | 74 (74.7) | 107 (72.8)b |
| β-blockers | 31 (64.6) | 61 (61.6) | 92 (62.6) |
| Calcium channel blockers | 34 (70.8) | 64 (64.6) | 98 (66.7) |
| Diuretics | 26 (54.2) | 59 (59.6) | 85 (57.8) |
| Metformin | 40 (83.3) | 76 (76.8) | 116 (78.9) |
| Insulin and analogues | 20 (41.7) | 49 (49.5) | 69 (46.9) |
| DPP4 inhibitors | 17 (35.4) | 31 (31.3) | 48 (32.7) |
| SGLT2 inhibitors | 17 (35.4) | 32 (32.3) | 49 (33.3) |
| GLP-1 analogues | 14 (29.2) | 23 (23.2) | 37 (25.2) |
| Sulphonylureas | 14 (29.2) | 17 (17.2) | 31 (21.1) |
| Statins | 37 (77.1) | 78 (78.8) | 115 (78.2) |
| Acetylsalicylic acid | 21 (43.8) | 49 (49.5) | 70 (47.6) |
| Proton pump inhibitors | 9 (18.8) | 30 (30.3) | 39 (26.5) |
| Parameter . | Placebo, n = 48 . | Fulacimstat, n = 99 . | Total, n = 147 . |
|---|---|---|---|
| Male sex, % | 40 (83.3) | 84 (84.8) | 124 (84.4) |
| Age, years | 66.5 ± 7.8 | 69.1 ± 6.3 | 68.2 ± 6.9 |
| BMI, kg/m2 | 31.2 ± 4.7 | 31.4 ± 4.9 | 31.3 ± 4.8 |
| Systolic blood pressure, mmHg | 139 ± 16 | 135 ± 13 | 136 ± 14 |
| Diastolic blood pressure, mmHg | 77 ± 9 | 74 ± 10 | 75 ± 10 |
| High albuminuria, % | 32 (66.7) | 78 (78.8) | 110 (74.8) |
| UACR at Visit 1, mg/g | 140 (31–2429) | 129 (29–2165) | 131 (29–2429) |
| eGFR ≤60 mL/min/1.73 m2, % | 22 (45.8) | 49 (49.5) | 71 (48.3) |
| eGFR at Visit 1, mL/min/1.73 m2 | 61.2 ± 16.5 | 60.5 ± 17.2 | 60.8 ± 16.9 |
| Medical history,a % | |||
| Arterial hypertension | 47 (97.9) | 98 (99.0) | 145 (98.6) |
| Cardiovascular comorbidities | 33 (68.7) | 62 (62.6) | 95 (64.6) |
| Hyperlipidaemia/dyslipidaemia | 25 (52.1) | 51 (51.5) | 76 (51.7) |
| Obesity | 19 (39.6) | 41 (41.4) | 60 (40.8) |
| Diabetic neuropathy | 16 (33.3) | 23 (23.2) | 39 (26.5) |
| Diabetic retinopathy | 10 (20.8) | 25 (25.3) | 35 (23.8) |
| Hypercholesterinaemia | 8 (16.7) | 25 (25.3) | 33 (22.4) |
| Comedication,a % | |||
| ACEis | 15 (31.3) | 24 (24.2) | 39 (26.5)b |
| Ang II receptor blockers (%) | 33 (68.7) | 74 (74.7) | 107 (72.8)b |
| β-blockers | 31 (64.6) | 61 (61.6) | 92 (62.6) |
| Calcium channel blockers | 34 (70.8) | 64 (64.6) | 98 (66.7) |
| Diuretics | 26 (54.2) | 59 (59.6) | 85 (57.8) |
| Metformin | 40 (83.3) | 76 (76.8) | 116 (78.9) |
| Insulin and analogues | 20 (41.7) | 49 (49.5) | 69 (46.9) |
| DPP4 inhibitors | 17 (35.4) | 31 (31.3) | 48 (32.7) |
| SGLT2 inhibitors | 17 (35.4) | 32 (32.3) | 49 (33.3) |
| GLP-1 analogues | 14 (29.2) | 23 (23.2) | 37 (25.2) |
| Sulphonylureas | 14 (29.2) | 17 (17.2) | 31 (21.1) |
| Statins | 37 (77.1) | 78 (78.8) | 115 (78.2) |
| Acetylsalicylic acid | 21 (43.8) | 49 (49.5) | 70 (47.6) |
| Proton pump inhibitors | 9 (18.8) | 30 (30.3) | 39 (26.5) |
| Parameter . | Placebo, n = 48 . | Fulacimstat, n = 99 . | Total, n = 147 . |
|---|---|---|---|
| Male sex, % | 40 (83.3) | 84 (84.8) | 124 (84.4) |
| Age, years | 66.5 ± 7.8 | 69.1 ± 6.3 | 68.2 ± 6.9 |
| BMI, kg/m2 | 31.2 ± 4.7 | 31.4 ± 4.9 | 31.3 ± 4.8 |
| Systolic blood pressure, mmHg | 139 ± 16 | 135 ± 13 | 136 ± 14 |
| Diastolic blood pressure, mmHg | 77 ± 9 | 74 ± 10 | 75 ± 10 |
| High albuminuria, % | 32 (66.7) | 78 (78.8) | 110 (74.8) |
| UACR at Visit 1, mg/g | 140 (31–2429) | 129 (29–2165) | 131 (29–2429) |
| eGFR ≤60 mL/min/1.73 m2, % | 22 (45.8) | 49 (49.5) | 71 (48.3) |
| eGFR at Visit 1, mL/min/1.73 m2 | 61.2 ± 16.5 | 60.5 ± 17.2 | 60.8 ± 16.9 |
| Medical history,a % | |||
| Arterial hypertension | 47 (97.9) | 98 (99.0) | 145 (98.6) |
| Cardiovascular comorbidities | 33 (68.7) | 62 (62.6) | 95 (64.6) |
| Hyperlipidaemia/dyslipidaemia | 25 (52.1) | 51 (51.5) | 76 (51.7) |
| Obesity | 19 (39.6) | 41 (41.4) | 60 (40.8) |
| Diabetic neuropathy | 16 (33.3) | 23 (23.2) | 39 (26.5) |
| Diabetic retinopathy | 10 (20.8) | 25 (25.3) | 35 (23.8) |
| Hypercholesterinaemia | 8 (16.7) | 25 (25.3) | 33 (22.4) |
| Comedication,a % | |||
| ACEis | 15 (31.3) | 24 (24.2) | 39 (26.5)b |
| Ang II receptor blockers (%) | 33 (68.7) | 74 (74.7) | 107 (72.8)b |
| β-blockers | 31 (64.6) | 61 (61.6) | 92 (62.6) |
| Calcium channel blockers | 34 (70.8) | 64 (64.6) | 98 (66.7) |
| Diuretics | 26 (54.2) | 59 (59.6) | 85 (57.8) |
| Metformin | 40 (83.3) | 76 (76.8) | 116 (78.9) |
| Insulin and analogues | 20 (41.7) | 49 (49.5) | 69 (46.9) |
| DPP4 inhibitors | 17 (35.4) | 31 (31.3) | 48 (32.7) |
| SGLT2 inhibitors | 17 (35.4) | 32 (32.3) | 49 (33.3) |
| GLP-1 analogues | 14 (29.2) | 23 (23.2) | 37 (25.2) |
| Sulphonylureas | 14 (29.2) | 17 (17.2) | 31 (21.1) |
| Statins | 37 (77.1) | 78 (78.8) | 115 (78.2) |
| Acetylsalicylic acid | 21 (43.8) | 49 (49.5) | 70 (47.6) |
| Proton pump inhibitors | 9 (18.8) | 30 (30.3) | 39 (26.5) |
| Parameter . | Placebo, n = 48 . | Fulacimstat, n = 99 . | Total, n = 147 . |
|---|---|---|---|
| Male sex, % | 40 (83.3) | 84 (84.8) | 124 (84.4) |
| Age, years | 66.5 ± 7.8 | 69.1 ± 6.3 | 68.2 ± 6.9 |
| BMI, kg/m2 | 31.2 ± 4.7 | 31.4 ± 4.9 | 31.3 ± 4.8 |
| Systolic blood pressure, mmHg | 139 ± 16 | 135 ± 13 | 136 ± 14 |
| Diastolic blood pressure, mmHg | 77 ± 9 | 74 ± 10 | 75 ± 10 |
| High albuminuria, % | 32 (66.7) | 78 (78.8) | 110 (74.8) |
| UACR at Visit 1, mg/g | 140 (31–2429) | 129 (29–2165) | 131 (29–2429) |
| eGFR ≤60 mL/min/1.73 m2, % | 22 (45.8) | 49 (49.5) | 71 (48.3) |
| eGFR at Visit 1, mL/min/1.73 m2 | 61.2 ± 16.5 | 60.5 ± 17.2 | 60.8 ± 16.9 |
| Medical history,a % | |||
| Arterial hypertension | 47 (97.9) | 98 (99.0) | 145 (98.6) |
| Cardiovascular comorbidities | 33 (68.7) | 62 (62.6) | 95 (64.6) |
| Hyperlipidaemia/dyslipidaemia | 25 (52.1) | 51 (51.5) | 76 (51.7) |
| Obesity | 19 (39.6) | 41 (41.4) | 60 (40.8) |
| Diabetic neuropathy | 16 (33.3) | 23 (23.2) | 39 (26.5) |
| Diabetic retinopathy | 10 (20.8) | 25 (25.3) | 35 (23.8) |
| Hypercholesterinaemia | 8 (16.7) | 25 (25.3) | 33 (22.4) |
| Comedication,a % | |||
| ACEis | 15 (31.3) | 24 (24.2) | 39 (26.5)b |
| Ang II receptor blockers (%) | 33 (68.7) | 74 (74.7) | 107 (72.8)b |
| β-blockers | 31 (64.6) | 61 (61.6) | 92 (62.6) |
| Calcium channel blockers | 34 (70.8) | 64 (64.6) | 98 (66.7) |
| Diuretics | 26 (54.2) | 59 (59.6) | 85 (57.8) |
| Metformin | 40 (83.3) | 76 (76.8) | 116 (78.9) |
| Insulin and analogues | 20 (41.7) | 49 (49.5) | 69 (46.9) |
| DPP4 inhibitors | 17 (35.4) | 31 (31.3) | 48 (32.7) |
| SGLT2 inhibitors | 17 (35.4) | 32 (32.3) | 49 (33.3) |
| GLP-1 analogues | 14 (29.2) | 23 (23.2) | 37 (25.2) |
| Sulphonylureas | 14 (29.2) | 17 (17.2) | 31 (21.1) |
| Statins | 37 (77.1) | 78 (78.8) | 115 (78.2) |
| Acetylsalicylic acid | 21 (43.8) | 49 (49.5) | 70 (47.6) |
| Proton pump inhibitors | 9 (18.8) | 30 (30.3) | 39 (26.5) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
